Caribou Biosciences, Inc. (NASDAQ:CRBU) Given Consensus Rating of “Buy” by Analysts

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) have earned an average rating of “Buy” from the five research firms that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $10.33.

A number of equities analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Bank of America dropped their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Citigroup reduced their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th.

Hedge Funds Weigh In On Caribou Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. US Bancorp DE boosted its stake in Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock worth $43,000 after buying an additional 26,467 shares during the period. Milestone Asset Management LLC boosted its stake in shares of Caribou Biosciences by 5.6% during the 4th quarter. Milestone Asset Management LLC now owns 163,789 shares of the company’s stock worth $260,000 after purchasing an additional 8,662 shares during the period. Thrive Wealth Management LLC bought a new position in Caribou Biosciences during the 4th quarter valued at about $51,000. Green Alpha Advisors LLC raised its position in Caribou Biosciences by 75.4% in the 4th quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock worth $288,000 after purchasing an additional 77,840 shares during the period. Finally, Barclays PLC lifted its stake in Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Trading Down 4.9 %

Shares of NASDAQ:CRBU opened at $1.35 on Friday. The stock has a 50 day moving average of $1.70 and a 200 day moving average of $1.94. The company has a market cap of $122.24 million, a PE ratio of -0.82 and a beta of 2.31. Caribou Biosciences has a 12-month low of $1.30 and a 12-month high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.02 million during the quarter, compared to analyst estimates of $3.37 million. Equities research analysts predict that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.